Millions of Seniors Can Now Get the Medicare GLP-1 Bridge $50 Copay for Weight Loss

Medicare crossed a line this month that it had refused to cross for more than twenty years, agreeing for the first time to cover a medication prescribed purely to help people lose weight. The change arrived quietly on July 1, 2026, in the form of an 18-month demonstration that offers eligible seniors a flat monthly price for some of the most sought-after and expensive drugs in America.

The program, formally the Medicare GLP-1 Bridge, lets qualifying Part D and Medicare Advantage members pay $50 for a 30-day supply of Wegovy, Zepbound, or a newly cleared daily pill called Foundayo. For a class of drugs that has routinely carried list prices above $1,000 a month, the arithmetic represents one of the largest single shifts in how older Americans access obesity treatment, and it reopens a debate Congress has ducked since the modern Medicare drug benefit was written.

The statutory ban that kept obesity drugs off Medicare

When lawmakers designed the Part D prescription benefit in the early 2000s, they wrote in an explicit exclusion for drugs used for weight loss. That language, a product of an era when appetite suppressants carried a poor safety reputation, has functioned as a hard wall ever since. Medicare would pay for a GLP-1 drug if a doctor prescribed it for type 2 diabetes, and later for cardiovascular risk, but never if the stated purpose was obesity itself.

The Bridge demonstration does not repeal that ban. Instead, it uses the federal government's authority to test payment models to route around it for a fixed window, running from July 1, 2026, through December 31, 2027. Officials have framed it as an experiment: a chance to measure cost, uptake, and health outcomes before Congress decides whether to make coverage permanent.

That framing matters because it marks the first time in over two decades that Medicare has agreed to cover a drug prescribed specifically for obesity rather than for a downstream condition like diabetes or heart disease. Advocates who have spent years arguing that obesity is a chronic disease worthy of treatment see the move as a validation of that position, even if it comes with an expiration date attached.

Medicare GLP-1 Bridge $50 Copay

The mechanics are deliberately simple at the counter. An eligible beneficiary pays $50 for each 30-day supply, and that figure does not change with the dose. Someone starting at a low titration dose and someone on a full maintenance dose pay the same amount, which removes the escalating cost that has driven many patients to abandon these drugs partway through treatment.

The fine print is where the Medicare GLP-1 Bridge $50 copay diverges from ordinary Part D coverage. The $50 payments do not count toward the Part D deductible, and they do not count toward the $2,100 annual out-of-pocket spending cap that otherwise protects Medicare drug spenders. There is also no low-income subsidy layered on top, meaning the $50 is the floor for everyone, including beneficiaries who normally receive extra help with drug costs.

That structure is a trade-off. Seniors get a predictable, relatively modest monthly price, but the money they spend on these drugs sits outside the safety net that caps their other pharmacy bills. For a patient managing several conditions, the Bridge copay is an additional, separate line item rather than a cost that accelerates them toward the annual ceiling.

Drugs Covered Under the Program

The demonstration covers a specific slate of products from the two companies that dominate this market. From Novo Nordisk, Wegovy is covered in both its injectable and newer tablet forms. From Eli Lilly, the program covers Zepbound, but only in its KwikPen presentation, along with Foundayo, a daily tablet that gives the program its first oral-only entrant designed for weight management.

The inclusion of pill formulations is significant. Injectable GLP-1s have long faced supply constraints and patient hesitation about needles, and an oral option lowers both barriers. Foundayo's arrival as a covered daily tablet, alongside Wegovy's tablet form, signals that the next phase of this drug class will be fought as much in pharmacies dispensing pills as in the injectable market that built these brands.

Notably, the list is a fixed menu rather than an open formulary. A beneficiary cannot simply bring any GLP-1 prescription to the counter and expect the Bridge price; the drug must be one of these covered products, prescribed under the program's rules.

Eligibility Thresholds by BMI and Condition

Eligibility is built on a tiered set of clinical thresholds rather than a single BMI number. A beneficiary qualifies with a body mass index of 35 or higher on its own. At a BMI of 30 or above, they also qualify if they have heart failure, uncontrolled hypertension, or chronic kidney disease. And at a BMI as low as 27, they qualify if they carry prediabetes, a prior heart attack or stroke, or peripheral artery disease.

There is a crucial carve-out on the other side. Patients who are already covered for GLP-1s through Medicare Part D for an approved condition, type 2 diabetes, sleep apnea, or fatty liver disease, are excluded from the Bridge. The program is designed to reach people who fall outside existing coverage, not to hand a cheaper price to those who already have a pathway.

KFF estimates that roughly 3.8 million Medicare beneficiaries met these criteria based on 2023 Part D enrollment data. That figure is large enough to reshape demand for these drugs, yet narrow enough to reflect the program's targeting: it is aimed at people with meaningful obesity and its associated conditions, not a general open door for anyone seeking to lose a few pounds.

Prior Authorization and the Lifestyle Requirement

Access is not automatic even for those who qualify on paper. A prescribing provider must submit prior authorization, and that paperwork has to document something specific: that the GLP-1 is being prescribed as part of a lifestyle program that includes diet and exercise. The drug, in the program's design, is a component of care rather than a standalone fix.

That requirement reflects both clinical consensus and a cost-control instinct. Studies of these medications consistently show that they work best paired with behavioral change, and weight tends to return when patients stop taking them. By tying coverage to a documented lifestyle program, the demonstration attempts to anchor the pharmaceutical intervention to the habits that sustain its results.

For patients, the practical effect is an extra step and a potential source of friction. Prior authorization can slow the start of treatment and, in some cases, become a point where prescriptions stall. How smoothly plans and providers process these requests will shape whether the 3.8 million eligible seniors actually translate into a comparable number of filled prescriptions.

Pricing Deals That Set Up the Launch

The Bridge did not emerge in isolation. It follows deals the Trump administration struck in November 2025 with Eli Lilly and Novo Nordisk to bring down GLP-1 prices. Those agreements produced two parallel tracks: the Medicare $50 copay path for eligible beneficiaries, and a direct-to-consumer discount option marketed through TrumpRx.gov for buyers outside the Medicare channel.

The dual structure is telling. The government secured a lower Medicare price for a defined population while also creating a retail discount avenue, letting the administration point to progress on drug costs for both seniors and the broader public. For the manufacturers, the arrangement trades margin per prescription for a vastly expanded pool of covered and discounted customers.

Whether that volume for price bargain proves durable is one of the open questions the demonstration is meant to answer. If uptake is high and outcomes improve, the pressure to extend coverage past December 2027 will be considerable. If costs balloon without clear health gains, the statutory ban that the Bridge sidesteps will look, to some in Congress, like it was there for a reason.

Costs and Timeline Seniors Should Weigh

For an individual beneficiary, the decision comes down to more than the sticker price. The Medicare GLP-1 Bridge $50 copay makes these drugs affordable in a way they have never been for this population, but the exclusion of those payments from the out-of-pocket cap means a full year on the program costs $600 that sits outside the usual protections. That is a manageable sum for many, a stretch for some, and worth modeling against a patient's other drug spending.

There is also the clock. Because the demonstration ends on December 31, 2027, patients who start now face uncertainty about what happens when it closes. If coverage is not extended, they could confront the full commercial price of a drug they have come to rely on, or the retreat of the weight they worked to lose. That looming cliff is the quiet cost embedded in an otherwise generous offer.

Still, the launch represents a genuine opening. Millions of older Americans who were told for two decades that Medicare simply would not pay for obesity treatment now have a path, however temporary and hedged with conditions, to some of the most effective weight-loss drugs ever brought to market. Whether that path becomes permanent will depend on the data the next 18 months produce, and on whether Congress finally decides to revisit the ban it wrote in a different era.